Wednesday, July 8, 2020

WuXi AppTec Appoints Dr. David Chang as CEO of WuXi Advanced Therapies Business Unit

SHANGHAI and PHILADELPHIA, June 1, 2020 -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announced today the appointment of Dr. David Chang as Chief Executive Officer of WuXi Advanced Therapies business unit (WuXi ATU), WuXi AppTec’s cell and...

WuXi AppTec: Collaborating Against COVID-19

WuXi AppTec is convening and working together with experts, from our company and around the world, for ongoing analysis of the COVID-19 pandemic. We are also partnering with other industry leaders on actions to address it. As we continue to collaborate with...

WuXi Advanced Therapies Launches New Closed Process CAR-T Cell Therapy Platform

World-class platform will enable biotechnology companies and researchers to accelerate the development, manufacturing and release of cell and gene therapies for patients May 18, 2020 – Philadelphia, PA - WuXi Advanced Therapies, a leading global Contract Development and Manufacturing...

WuXi AppTec Reports Solid First-Quarter 2020 Results

Revenue Up 15.1% Year-Over-Year to RMB3,188 Million Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 10.8% Year-Over-Year to RMB576 Million Adjusted Diluted Non-IFRS EPS Up 9.4% Year-Over-Year to RMB0.351  (SHANGHAI,...

WuXi AppTec Reports Strong 2019 Annual Results

WuXi AppTec Reports Strong 2019 Annual Results Revenue Growth Accelerated 33.9% Year-Over-Year to RMB12,872 Million Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 38.2% Year-Over-Year to RMB2,407 Million Adjusted Diluted...

Subscribe to our Newsletter

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS